Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
BC Liao, CC Lin, JH Lee, JCH Yang - Lung Cancer, 2017 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
Postprogression outcomes for osimertinib versus standard-of-care egfr-tki in patients with previously untreated egfr-mutated advanced non–small cell lung cancer
D Planchard, MJ Boyer, JS Lee, A Dechaphunkul… - Clinical Cancer …, 2019 - AACR
Purpose: In the phase III FLAURA study, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M–mutated non–small cell lung cancer previously treated with epidermal growth …
H Akamatsu, Y Toi, H Hayashi, D Fujimoto… - JAMA …, 2021 - jamanetwork.com
Importance Although treatment with first-generation epidermal growth factor receptor (EGFR)–
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …
tyrosine kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …
Treatment options for EGFR T790M-negative EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer
The introduction of first-and second-generation EGFR-tyrosine kinase inhibitors
(TKIs)(gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small …
(TKIs)(gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small …
Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
V Hirsh - Therapeutic advances in medical oncology, 2018 - journals.sagepub.com
Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib, afatinib and osimertinib, are currently available for the management of EGFR …
gefitinib, afatinib and osimertinib, are currently available for the management of EGFR …
Comparison between second-and third-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with non-small-cell lung …
S Mitsuya, K Tsuruoka, K Kanaoka… - Anticancer …, 2021 - ar.iiarjournals.org
Background: For epidermal growth factor receptor (EGFR)-mutated non-small cell lung
cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to …
cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to …
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
9507 Background: First-line treatment with an EGFR tyrosine kinase inhibitor (TKI) is
standard of care for patients (pts) with EGFR-mutated NSCLC. The EGFR TKI osimertinib is …
standard of care for patients (pts) with EGFR-mutated NSCLC. The EGFR TKI osimertinib is …
Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
JRE Choo, CS Tan, RA Soo - Targeted oncology, 2018 - Springer
The treatment of lung cancer has changed dramatically with the development of tyrosine
kinase inhibitors (TKIs) that target sensitizing somatic mutations of the epidermal growth …
kinase inhibitors (TKIs) that target sensitizing somatic mutations of the epidermal growth …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
MS Holleman, H van Tinteren, HJM Groen… - OncoTargets and …, 2019 - Taylor & Francis
Background EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including afatinib, dacomitinib,
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …
erlotinib, gefitinib, and osimertinib have proven efficacy in terms of progression-free survival …